Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00379808 · ClinicalTrials.gov registry record · NA

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

A NA study of Coronary Heart Disease, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT00379808: Completed NA study of Coronary Heart Disease, sponsored by University of Florida.

NCT00379808 is a NA study of Coronary Heart Disease that has completed, run by University of Florida. The registered enrollment target is 22 participants, below the 1,487-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00379808, a NA study of Coronary Heart Disease, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether a particular substance involved in inflammation, called leukotrienes, is involved in causing heart disease to occur or to progress.

Primary Outcome

measured in a CLIA clinical laboratory facility (Quest Diagnostics, Tampa, FL)

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG montelukast

Study Locations (1)

Florida

  • University of Florida Family Practice Medical Group Clinic - Gainesville

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2006-07
Est. Completion 2009-08
Phase NA
University of Florida

1,106 total trials

What the finished NCT00379808 record still lists

NCT00379808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,487-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Coronary Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00379808 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT00379808 about?

NCT00379808 is a clinical study titled "Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease". The purpose of this study is to determine whether a particular substance involved in inflammation, called leukotrienes, is involved in causing heart disease to occur or to progress.

What is the current status of trial NCT00379808?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2006-07. Estimated completion is 2009-08.

What conditions does trial NCT00379808 study?

This clinical trial studies the following conditions: Coronary Heart Disease.

What interventions are being tested in trial NCT00379808?

The interventions under investigation include: Placebo (DRUG), montelukast (DRUG).

Who is sponsoring clinical trial NCT00379808?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00379808 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00379808's enrollment target sits among peer trials

22 18th of 19 higher than 2 of 19 other Coronary Heart Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00379808, the US trial registry maintained by the National Library of Medicine. NCT00379808 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.